SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments

Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xirui, Yuan, Hao, Yang, Zipeng, Hu, Xiaoyu, Mahmmod, Yasser S., Zhu, Xiaojing, Zhao, Cuiping, Zhai, Jingbo, Zhang, Xiu-Xiang, Luo, Shengjun, Wang, Xiao-Hu, Xue, Mengzhou, Zheng, Chunfu, Yuan, Zi-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780920/
https://www.ncbi.nlm.nih.gov/pubmed/36560555
http://dx.doi.org/10.3390/vaccines10122145
Descripción
Sumario:Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus.

Ejemplares similares